While Sarepta Therapeutics Inc has overperformed by 5.83%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRPT fell by -84.18%, with highs and lows ranging from $154.13 to $16.88, whereas the simple moving average fell by -78.14% in the last 200 days.
On June 20, 2025, William Blair Downgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) to Mkt Perform. A report published by TD Cowen on June 18, 2025, Downgraded its rating to ‘Hold’ for SRPT. Morgan Stanley June 16, 2025d its ‘Overweight’ rating to ‘Equal-Weight’ for SRPT, as published in its report on June 16, 2025. H.C. Wainwright’s report from June 16, 2025 suggests a price prediction of $10 for SRPT shares, giving the stock a ‘Sell’ rating. Cantor Fitzgerald also rated the stock as ‘Neutral’.
Analysis of Sarepta Therapeutics Inc (SRPT)
Further, the quarter-over-quarter increase in sales is 80.15%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Sarepta Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -23.61% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.46, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and SRPT is recording an average volume of 5.36M. On a monthly basis, the volatility of the stock is set at 6.92%, whereas on a weekly basis, it is put at 7.22%, with a gain of 11.03% over the past seven days. Furthermore, long-term investors anticipate a median target price of $51.76, showing growth from the present price of $19.23, which can serve as yet another indication of whether SRPT is worth investing in or should be passed over.
How Do You Analyze Sarepta Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.89%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 90.23% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
